Search results
Results from the WOW.Com Content Network
Topical glucocorticoid phobia is a concern or fear about using topical glucocorticoids, which is commonly found among patients with atopic dermatitis and their caregivers. [29] This phenomenon has been identified in more than 15 countries globally, including Canada , France , Japan , the United Kingdom , and the United States . [ 30 ]
Synthetic Glucocorticoid Equivalent Dose (mg) Anti-inflammatory Activity 1 Mineralocorticoid Activity 1 Biological Half Life (hrs) References Short-to medium-acting glucocorticoids: Hydrocortisone 20 1 1 8–12 [25] [26] Cortisone 25 0.8 0.8 8–12 [25] [26] Prednisone 5 4 0.3 12–36 [25] [26] Prednisolone 5 4–5 0.3 12–36 [25] [26 ...
Deracoxib is a coxib class nonsteroidal anti-inflammatory drug (NSAID). [3] Like other NSAIDs, its effects are caused by inhibition of cyclooxygenase (COX) enzymes. [7] At the doses used to treat dogs, deracoxib causes greater inhibition of COX-2 than of COX-1, [3] but at doses twice those recommended for use in dogs, deracoxib significantly inhibits COX-1 as well.
For treating atopic dermatitis, newer (second generation) corticosteroids, such as fluticasone propionate and mometasone furoate, are more effective and safer than older ones. They are also generally safe and do not cause skin thinning when used in intermittently to treat atopic dermatitis flare-ups.
Disadvantages of mitotane as a treatment include the side effects and the requirement for blood test monitoring. Issues can arise when too much of the adrenal cortex becomes eroded. Approximately 30% of dogs will experience a reaction in response to treatment with mitotane; prednisone may be used as an antidote. In the event of a reaction ...
Methylprednisolone (Depo-Medrol, Medrol, Solu-Medrol) is a synthetic glucocorticoid, primarily prescribed for its anti-inflammatory and immunosuppressive effects. [4] [5] [6] It is either used at low doses for chronic illnesses or used concomitantly at high doses during acute flares.
The term "steroid dementia" was coined by Varney et al. (1984) in reference to the effects of long-term glucocorticoid use in 1,500 patients. [3] While the condition generally falls under the classification of Cushing's syndrome , the term "steroid dementia syndrome" is particularly useful because it recognizes both the cause of the syndrome ...
[209] [210] [211] Spironolactone "acts at the basolateral side of the upper-distal tubule as well as in the collecting tubule," and does not have glucocorticoid-like effects at these specific sites; it can sometimes be prescribed as an alternative to glucocorticoids for patients with Glucocorticoid-Remediable Aldosteronism characterized by ...